Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 6/20 | 0.34 |
| ▸ | HTR1A | P08908 | 4/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.34 |
| ▸ | DRD3 | P35462 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707969 | 0.95 | CCR5 (0.35) | CCR5HTR7MEN1KMT2ALMNA | |
| SCHEMBL3446634 | 0.89 | MEN1 (0.34) | CCR5MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL4441082 | 0.88 | HTR7 (0.35) | HTR7HTR1AHTR2ADRD3MEN1 | |
| SCHEMBL4437206 | 0.88 | HTR7 (0.35) | HTR7HTR1AHTR2ADRD3MEN1 | |
| SCHEMBL4444921 | 0.87 | CCR5 (0.34) | CCR5HTR7MEN1KMT2ALMNA | |
| SCHEMBL4444561 | 0.86 | CCR5 (0.34) | CCR5HTR7MEN1KMT2ALMNA | |
| SCHEMBL4553417 | 0.84 | DRD3 (0.35) | HTR7HTR1AHTR2ADRD3MEN1 | |
| SCHEMBL4554297 | 0.82 | CHRM1 (0.35) | CCR5HTR7HTR1AHTR2ADRD3 | |
| SCHEMBL4279426 | 0.74 | OPRL1 (0.39) | HTR1AHTR2ADRD3 | |
| SCHEMBL4274132 | 0.74 | MC4R (0.37) | HTR1AHTR2ADRD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| EP-2262791-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009124734-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264407-A1 | Substituted Sulfonamide Compounds | CNR1, SUCNR1, OPRL1 | CCR5 1218/4885HTR7 522/4885HTR1A 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.